Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non-Current Assets (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Non-Current Assets for 3 consecutive years, with $40.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Non-Current Assets fell 10.55% to $40.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$220.0 million, a 65.88% increase, with the full-year FY2024 number at $40.4 million, down 10.55% from a year prior.
  • Non-Current Assets was $40.4 million for Q4 2024 at Centessa Pharmaceuticals, down from $45.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $45.2 million in Q4 2023 to a low of -$384.3 million in Q1 2023.
  • A 3-year average of -$85.2 million and a median of $6.6 million in 2022 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 588.32% in 2023; the steepest drop was 38803.93% in 2023.
  • Centessa Pharmaceuticals' Non-Current Assets stood at $6.6 million in 2022, then skyrocketed by 588.32% to $45.2 million in 2023, then dropped by 10.55% to $40.4 million in 2024.
  • Per Business Quant, the three most recent readings for CNTA's Non-Current Assets are $40.4 million (Q4 2024), $45.2 million (Q4 2023), and $44.9 million (Q3 2023).